Greenwich Lifesciences

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by 32.95% to $11.46 Tuesday afternoon after the FDA removed the clinical hold on the company's Flamingo-01 Phase 3 trial of GP2. Greenwich Lifesciences says through discussions with the FDA and testing of GP2 in the.

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Greenwich Lifesciences (GLSI) stock is heading higher on Tuesday after the FDA lifted a hold on a Phase III clinical trial. The post Why Is Greenwich Lifesciences (GLSI) Stock Up Today?

Why Is Greenwich Lifesciences (GLSI) Stock Up Today?

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Resume Stock Repurchase Program

Greenwich LifeSciences to Resume Stock Repurchase Program

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was originally expected to initiate in 2020 is primarily to blame.

Greenwich LifeSciences: A First Look

Greenwich LifeSciences is a stock relatively new to the market and lesser-known, as it became public in September of 2020. Not long after, the stock skyrocketed over 1000% on early data that the company's GP2 treatment reduced breast cancer recurrences to zero.

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

AstraZeneca

Biogen

Entera Bio Ltd

GameStop

Longeveron

Roche Holding AG

Riot Blockchain

TRACON Pharmaceuticals

SPDR S&P Biotech ETF

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech Stocks appeared first on InvestorPlace.

Recession Fears are Creating a Golden Opportunity for Biotech Stocks

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely.

3 Stocks Insiders Are Buying on Market Turbulence

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 low patients, who did not receive trastuzumab after surgery.

Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference

News for Greenwich Lifesciences Stock (GLSI)